Dianthus Therapeutics, Inc. /DE/ (DNTH) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-155.38M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.81× | Operating cash flow / net income. Period ending 2026-06-30. $-155.38M ÷ $-192.25M ≈ 0.81× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -155.38M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -192.25M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-155.38M | (m) | (m) | (m) | (m) | $-192.25M | (m) | (m) | (m) | 0.81× |
| 2026-03-31 | (m) | (m) | $-130.29M | (m) | (m) | (m) | (m) | $-173.66M | (m) | (m) | (m) | 0.75× |
| 2025-12-31 | (m) | (m) | $-129.06M | (m) | (m) | $2.04M | (m) | $-162.34M | (m) | (m) | (m) | 0.80× |
| 2025-09-30 | (m) | (m) | $-109.52M | (m) | (m) | $3.08M | (m) | $-126.34M | (m) | (m) | (m) | 0.87× |
| 2025-06-30 | (m) | (m) | $-100.23M | (m) | (m) | $4.85M | (m) | $-114.75M | (m) | (m) | (m) | 0.87× |
| 2025-03-31 | (m) | (m) | $-90.87M | (m) | (m) | $6.52M | (m) | $-100.73M | (m) | (m) | (m) | 0.90× |
| 2024-12-31 | (m) | (m) | $-78.18M | (m) | (m) | $6.24M | (m) | $-84.97M | (m) | (m) | (m) | 0.92× |
| 2024-09-30 | (m) | (m) | $-62.59M | (m) | (m) | (m) | (m) | $-67.09M | (m) | (m) | (m) | 0.93× |
| 2024-06-30 | (m) | (m) | $-51.31M | (m) | (m) | (m) | (m) | $-56.68M | (m) | (m) | (m) | 0.91× |
| 2024-03-31 | (m) | (m) | $-41.52M | (m) | (m) | (m) | (m) | $-50.21M | (m) | (m) | (m) | 0.83× |
| 2023-12-31 | (m) | (m) | $-36.86M | (m) | (m) | (m) | (m) | $-43.55M | (m) | (m) | (m) | 0.85× |
| 2023-09-30 | (m) | (m) | $-71.88M | (m) | (m) | (m) | (m) | $-91.13M | (m) | (m) | (m) | 0.79× |
| 2023-06-30 | $-73.04M | (m) | $-72.64M | $403.00K | (m) | (m) | (m) | $-68.73M | (m) | (m) | (m) | 1.06× |
| 2023-03-31 | $-83.48M | (m) | $-82.95M | $532.00K | (m) | (m) | (m) | $-82.72M | (m) | (m) | (m) | 1.00× |
| 2022-12-31 | $-67.40M | (m) | $-67.09M | $314.00K | (m) | (m) | (m) | $-76.46M | (m) | (m) | (m) | 0.88× |
| 2022-09-30 | $-66.42M | (m) | $-66.09M | $329.00K | (m) | (m) | (m) | $-75.54M | (m) | (m) | (m) | 0.87× |
| 2022-06-30 | $-67.65M | (m) | $-66.35M | $1.30M | (m) | (m) | (m) | $-76.90M | (m) | (m) | (m) | 0.86× |
| 2022-03-31 | $-63.78M | (m) | $-62.50M | $1.28M | (m) | (m) | (m) | $-76.56M | (m) | (m) | (m) | 0.82× |
| 2021-12-31 | $-60.80M | (m) | $-59.53M | $1.26M | (m) | (m) | (m) | $-71.14M | (m) | (m) | (m) | 0.84× |
| 2021-09-30 | $-59.04M | (m) | $-57.57M | $1.46M | (m) | (m) | (m) | $-69.98M | (m) | (m) | (m) | 0.82× |
| 2021-06-30 | $-58.29M | (m) | $-57.94M | $351.00K | (m) | (m) | (m) | $-70.23M | (m) | (m) | (m) | 0.82× |
| 2021-03-31 | $-64.42M | (m) | $-64.14M | $276.00K | (m) | (m) | (m) | $-72.38M | (m) | (m) | (m) | 0.89× |
| 2020-12-31 | $-64.42M | (m) | $-64.02M | $400.00K | (m) | (m) | (m) | $-74.94M | (m) | (m) | (m) | 0.85× |
| 2020-09-30 | $-66.26M | (m) | $-65.92M | $340.00K | (m) | $0.00 | (m) | $-80.04M | (m) | (m) | (m) | 0.82× |
| 2020-06-30 | $-63.85M | (m) | $-63.00M | $850.00K | (m) | $0.00 | (m) | $-83.35M | (m) | (m) | (m) | 0.76× |
| 2020-03-31 | $-60.76M | (m) | $-58.82M | $1.94M | (m) | $0.00 | (m) | $-81.98M | (m) | (m) | (m) | 0.72× |
| 2019-12-31 | $-60.16M | (m) | $-57.10M | $3.06M | (m) | $0.00 | (m) | $-76.77M | (m) | (m) | (m) | 0.74× |
| 2019-09-30 | $-61.36M | (m) | $-54.10M | $7.26M | (m) | $0.00 | (m) | $-70.20M | (m) | (m) | (m) | 0.77× |
| 2019-06-30 | $-62.34M | (m) | $-53.14M | $9.20M | (m) | $0.00 | (m) | $-65.22M | (m) | (m) | (m) | 0.81× |
| 2019-03-31 | $-55.98M | (m) | $-47.22M | $8.76M | (m) | $0.00 | (m) | $-61.17M | (m) | (m) | (m) | 0.77× |
| 2018-12-31 | $-49.56M | (m) | $-41.89M | $7.67M | (m) | $0.00 | (m) | $-57.52M | (m) | (m) | (m) | 0.73× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $22.12M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $31.22M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | $-41.84M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-24.46M | (m) | $-22.26M | $2.20M | (m) | $0.00 | (m) | $-35.49M | (m) | (m) | (m) | 0.63× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-6.67M | (m) | $-6.53M | $139.00K | (m) | $0.00 | (m) | $-9.43M | (m) | (m) | (m) | 0.69× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |